Premium
Low Dose Methptrexate and Doxorubicin in Hormone‐resistant Prostatic Cancer
Author(s) -
SMITH M. F.,
LAWSON A. H.,
KIRK D.,
KAYE S. B.
Publication year - 1990
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1990.tb14798.x
Subject(s) - doxorubicin , cancer , hormone , medicine , oncology , chemotherapy
Summary— A group of 24 patients, all of whom had progressive disease following initial hormone therapy for advanced prostatic carcinoma, were given intravenous methotrexate (30 mg/m 2 ) and doxorubicin (15 mg/m 2 ) at 2‐week intervals for a planned 6‐treatment course. Seventeen patients completed the full course. Assessment included “quality of life” criteria, using the subjective assessment of performance status, severity of pain and analgesic consumption. Over half of the patients improved in each of these modalities and 8 (33%) improved in all 3. As toxicity was acceptable, low dose chemotherapy may have a part to play in these patients who present a difficult management problem.